an overview of the VRX news
Valeant Pharmaceuticals (VRX -19.7%) is getting pummeled in early trading after perennial bear Citron Research issued a new report today titled, "Valeant, Could this be the Pharmaceutical Enron?"
The report accuses the company of routing its business through phantom...